A phase 3 clinical trial investigating ST-100 for the treatment of dry eye disease did not meet its primary endpoint but ...

Topline data were announced from a phase 3 trial evaluating ST-100 ophthalmic solution for the treatment of dry eye disease.

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate that it can increase tear production in a phase 3 test.

Researchers have found in a phase 3 trial that phentolamine ophthalmic solution 0.75% led to significant improvements in ...

Global Ophthalmic Drugs Market is valued at approximately USD 38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.10% over the forecast period 2024-2032. Read the ...

Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist. Read why ALC stock is a hold.

All eye drop users should check out the FDA's list of 26 different eye drops that could cause infection or even blindness. The FDA has reported that Velocity Pharma manufactured its eye drops under ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day. Approval of Tryptyr was based on the results of two phase 3 clinical ...

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ...

The Food and Drug Administration (FDA) has approved Tryptyr ® (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease.. The active ingredient in Tryptyr ...

Opus Genetics has released positive topline results from LYNX-2, its phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in ...